Shanghai Kehua Bio-Engineering Co.,Ltd. (ASX: 002022) has announced that it has obtained a Medical Device Registration Certificate for an in-vitro diagnostic reagent from the Shanghai Municipal Medical Products Administration.
The registered product is the Complement C1q Assay Kit (Latex Immunoturbidimetric Method).
This kit is intended for use by medical institutions to conduct the quantitative in-vitro determination of Complement C1q levels in human serum and plasma samples.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.